Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Hill

Showing results (121-130 of 127) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 127 results.
The Oncologist|February 8, 2021
Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple MyelomaDickran Kazandjian, Alexander Dew, Elizabeth Hill, et al.
Acta Neuropathologica|March 30, 2026
Correction: Intracellular trafficking SNARE protein, syntaxin-6, modifies prion cellular phenotypes and risk of disease development in vivoElizabeth Hill, Mitali M Patel, Juan M Ribes, et al.
Science Advances|November 15, 2024
H<sub>2</sub>S-Prdx4 axis mitigates Golgi stress to bolster tumor-reactive T cell immunotherapeutic responseNathaniel Oberholtzer, Paramita Chakraborty, Mohamed Faisal Kassir, et al.
Nature Communications|June 2, 2026
Sphingosine kinase-2 inhibition promotes immunogenic differentiation of myeloid-derived suppressor cells through an Acetyl-CoA carboxylase-phosphatidylcholine axisParamita Chakraborty, Shilpak Chatterjee, Mohamed Faisal Kassir, et al.
JAMA Oncology|September 16, 2021
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled TrialDickran Kazandjian, Elizabeth Hill, Alexander Dew, et al.
Brain : a Journal of Neurology|January 27, 2025
Multiomic analyses direct hypotheses for Creutzfeldt-Jakob disease risk genesFahri Küçükali, Elizabeth Hill, Tijs Watzeels, et al.
Plos One|July 30, 2024
Genome wide association study of clinical duration and age at onset of sporadic CJDHolger Hummerich, Helen Speedy, Tracy Campbell, et al.
Pageof 13

Showing results (121-130 of 127) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 127 results.
The Oncologist|February 8, 2021
Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple MyelomaDickran Kazandjian, Alexander Dew, Elizabeth Hill, et al.
Acta Neuropathologica|March 30, 2026
Correction: Intracellular trafficking SNARE protein, syntaxin-6, modifies prion cellular phenotypes and risk of disease development in vivoElizabeth Hill, Mitali M Patel, Juan M Ribes, et al.
Science Advances|November 15, 2024
H<sub>2</sub>S-Prdx4 axis mitigates Golgi stress to bolster tumor-reactive T cell immunotherapeutic responseNathaniel Oberholtzer, Paramita Chakraborty, Mohamed Faisal Kassir, et al.
Nature Communications|June 2, 2026
Sphingosine kinase-2 inhibition promotes immunogenic differentiation of myeloid-derived suppressor cells through an Acetyl-CoA carboxylase-phosphatidylcholine axisParamita Chakraborty, Shilpak Chatterjee, Mohamed Faisal Kassir, et al.
JAMA Oncology|September 16, 2021
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled TrialDickran Kazandjian, Elizabeth Hill, Alexander Dew, et al.
Brain : a Journal of Neurology|January 27, 2025
Multiomic analyses direct hypotheses for Creutzfeldt-Jakob disease risk genesFahri Küçükali, Elizabeth Hill, Tijs Watzeels, et al.
Plos One|July 30, 2024
Genome wide association study of clinical duration and age at onset of sporadic CJDHolger Hummerich, Helen Speedy, Tracy Campbell, et al.
Pageof 13